Brind.

A company named Anika plans to file the final PMA module with the FDA regarding its study on articular knee cartilage defects.

1 report, 1 independent Updated Jul 30

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA AnikaKnee

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Anika
German musician

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 30GlobeNewswireAnika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update Hyalofast consistently demonstrated improvements over mi